MMA
CRVS icon

Miracle Mile Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Miracle Mile Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Buy
+30,000
New +$479K 0.01% 611

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Miracle Mile Advisors's CRVS Position: Q1 2026 in Review

Miracle Mile Advisors opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 30,000 shares worth $439K. The stake represents 0.01% of the portfolio and ranks #611 among its holdings.

164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Miracle Mile Advisors held 30,000 shares of Corvus Pharmaceuticals worth $439K as of Q1 2026.
  • Corvus Pharmaceuticals was a new Miracle Mile Advisors position in Q1 2026.
  • Corvus Pharmaceuticals made up 0.01% of Miracle Mile Advisors's portfolio in Q1 2026, its #611 holding.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Miracle Mile Advisors's 13F filing for Q1 2026, filed 8 Apr 2026.